DBV Technologies S.A.
DBVTDBV Technologies S.A. is a biopharmaceutical company focused on developing and commercializing innovative immunotherapy solutions for the treatment of food allergies. The company's flagship product, Viaskin, uses a patch-based delivery system aimed at desensitizing patients to specific allergens, particularly peanut allergies. Founded in France, DBV Technologies aims to address unmet medical needs through its proprietary epicutaneous immunotherapy platform.
Company News
DBV Technologies completed the last patient visit in its Phase 3 VITESSE clinical trial for a peanut allergy patch targeting children aged 4-7 years. The company expects to release topline data in Q4 2025 and remains committed to developing a non-invasive food allergy treatment.
The Dow Jones index closed higher by around 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insi...
DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
"The New England Journal of Medicine" reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
Check these three penny stocks out for your watchlist The post Penny Stocks to Buy With Gains in After Hours? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
